- Home
- EBON vs TOVX Comparison
EBON vs TOVX Comparison
Compare EBON & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBON | TOVX |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 16.4M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | EBON | TOVX |
|---|---|---|
| Price | $2.47 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 3.7K | ★ 24.1M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.61 | $0.16 |
| 52 Week High | $5.90 | $1.47 |
Technical Indicators
Market Signals| Indicator | EBON | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 62.90 |
| Support Level | $2.31 | $0.38 |
| Resistance Level | $2.91 | $0.52 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 62.74 | 56.14 |
Price Performance
Historical ComparisonAbout EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.